Pharmaceuticals
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Pro...
2021-05-03 09:30
4561
I-Mab Announces Upcoming Participation at May Conferences
SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in May. ...
2021-04-29 20:00
3643
I-Mab Filed 2020 Annual Report on Form 20-F
SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20...
2021-04-28 20:00
2041
Samsung Biologics Reports First Quarter 2021 Financial Results
* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit of KRW 74.3 billion increased 19% compared to Q1'20. * Q1'21 operating margin held steady at 28%. * All manufacturing facilities remain fully operational, without any disruptions caused by the COV...
2021-04-28 16:37
4857
New Distribution Facility Expands Bushu Pharma's Gateway to Asia (GTA) Services
KAWAGOE, Japan, April 28, 2021 /PRNewswire/ -- Bushu Pharmaceuticals Ltd. (hereinafter "Bushu Pharma") has established the Bushu Pharma Kazo Packaging Center located within the Kazo Pharmaceuticals Joint Distribution Center of Chuo Unyu Company ("Chuo Unyu") to carry out inspection, labeling, pac...
2021-04-28 14:00
1441
Bushu Pharma's Collaboration with Suzuken Group Expands Services for Specialty Pharmaceuticals
KAWAGOE, Japan, April 27, 2021 /PRNewswire/ -- -Establishment of New Business Alliance and Facility to Provide Comprehensive Support for New Product Launches for Manufacturers Aiming to Enter Japan Market- Bushu Pharmaceuticals Ltd. (hereinafter "Bushu Pharma") has entered into a business allian...
2021-04-27 14:00
2350
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...
2021-04-26 19:00
2215
Vaccines: More cooperation, less speculation
BEIJING, April 22, 2021 /PRNewswire/ -- A news report by China.org.cn on China's attitude towards China-US trade friction: Recently, there have been media reports saying that a Chinese official "admitted" low effectiveness of the country's COVID-19 vaccines. Given that many countries have alread...
2021-04-22 21:00
2070
Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."
INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the
world's leading contract development and manufacturing organization, celebrated
the 10th anniversary of its founding today at its global headquarters in
Songdo, Incheon via a virtual ceremony.
2021-04-21 19:00
2011
China Biologic Announces Completion of Going Private Transaction
BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...
2021-04-21 04:30
5824
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...
2021-04-20 20:54
1330
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration
SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...
2021-04-20 08:30
2041
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...
2021-04-19 20:30
3709
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
2021-04-19 20:15
2167
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...
2021-04-19 08:00
1945
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide
SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...
2021-04-16 18:29
5823
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...
2021-04-15 18:20
5974
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Rese...
2021-04-13 14:55
4113
PharmAbcine presents the non-clinical data of PMC-309 at AACR 2021
DAEJEON, South Korea, April 12, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring the non-clinical data of PMC-309 at American Associatio...
2021-04-12 20:00
1852
Yiling Pharmaceutical doubled its performance through innovation in 2020
SHIJIAZHUANG, China, April 12, 2021 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) released its 2020 annual report on Thursday. It achieved an operating revenue ofRMB 8.782 billion in 2020, with a year-on-year growth of 50.76%; and net profit attributed to equity holders ofRMB 1.219 billion, w...
2021-04-12 17:07
5205
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 318 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 308 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 292 media titles]
2026-01-27 18:00
